Table 2.

Rate estimations of long-term symptoms, loosely organized by frequency, from clinical patients recovered from acute features of COVID-19. A similar reference population is compared with to disentangle the effects of the COVID-19 pandemic from SARS-CoV-2 infection. Only symptoms that could have a primary or secondary effect on cognition are included.

	Clinical COVID-19 survivor	Comparison population
≥ 1 Symptom	50%† [122], 76%‡ [151]	-
Chest CT abnormalities	71%† [152], 53‡% [151]	-
Fatigue	53%** [123], 28-53%† [122,124], 63%‡ [151]	9-22% [122,153]
Myocardial inflammation	30-60%† [154,155]	-
Psychomotor coordination impairment	57%† [127]	-
Executive function impairment	50%† [127]	-
PTSD	28%** [126]	3-17% [156,157]
Loss of concentration	26%** [125], 33%† [127]	-
Verbal fluency loss	32%† [127]	-
Insomnia/sleep disturbance	8-40%** [125,126], 18%† [122], 26%‡ [151]	5-32% [122,156]
Depression	21-31%** [125,126], 4.3%† [122], 23%‡ [151]	1-28% [122,156,157]
Memory loss	18%** [125], 24%† [127]	-
Pulmonary function abnormalities	21-58%† [122,158], 22-56%‡ [151]	5% [122]
Resting heart rate increase	11%† [122]	0% [122]
Hematuria (kidney)	57%* [159]	-
Proteinuria (kidney)	31%* [159]	-
Liver ALT, AST/ALT, GGT & ALP Levels	*[160]	-

^*= Measurements at Hospital Discharge.

^**= Measurements at 1 month.

^†= Measurements at 3 months.

^‡= Measurement at 6 months.